heparin at therapeutic dose for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 mild to moderate meta-analysis
RAPID (Sholzberg) NCT04362085		RCT	heparin at therapeutic dose	standard of care	COVID-19 mild to moderate	some concern	228/237	suggested	suggested 78 % decrease in deaths,death D28 with a moderate degree of certainty due to some concern in risk of bias inconclusive 31 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 mild to moderate meta-analysis